This is a powerful antiviral, tested successfully for herpes types I and II, as well as non-specific viral infections. It contains the monoester of the acid lauric acid. Monolaurin has had good results in studies of Shingles, Herpes virus, Epstein Bar virus, and hepatitis B and C virus which is closely related to the herpes virus. Monolaurin shows antibacterial effects against a range of bacteria including antibiotic-resistant bacteria called Staphylococcus aureus (Staph).

According to a 2013 study, monolaurin is effective both in vitro and in living beings against certain strains of Staph infection.

Although this study did not use human participants, it did show monolaurin's effectiveness at killing bacterial infection in mice.

Other research indicates that monolaurin can inhibit the activity of other types of bacteria such as Escherichia coli (E. coli) and Bacillus subtilis.

In 2007, the Journal of Drugs in Dermatology published a study that compared monolaurin and six common antibiotics in the treatment of skin infections. The antibiotics included penicillin, oxacillin, and vancomycin.

The study concluded that monolaurin demonstrated "statistically significant in vitro broad-spectrum sensitivity" against the bacteria responsible for the skin infections. Most of the bacteria also did not display any resistance to the monolaurin.

There are many antibiotic-resistant bacteria that no longer respond to medications. Monolaurin might be helpful, and is cost-effective to use.

Antiviral

Monolaurin is reported to inhibit several lipid-coated viruses that affect humans and animals, including:

cytomegalovirus
measles
Herpes simplex-1
Herpes simplex-2
HIV
visna virus
Epstein-Barr virus
influenza
pneumonovirus
Recent research on female primates indicates that daily application of monolaurin vaginal gel may reduce the risk of contracting SIV, the primate form of HIV

In stock

in stock

In stock